BCL2 and cancer: The material displayed significant changes in Raman signals, exhibiting multimodal synergistic cancer therapy by combining PT, genetic, and chemotherapeutic methods (Figure 17I).[47a] SERS imaging of tumors was performed using Raman dye (Cy5)‐labeled nucleic acids (AntiSense OligoNucleotide (ASON) to specifically target and bind cell surface oncogenes (BCL2) (Au@GO NP‐BCL2‐NACs) via π‐π stacking.